

MAY 8 2007

K071162

Agfa Corporation

Premarket Notification: Computed Radiography Systems With NX 2.X Workstations

510(k) Summary DX-Si

Common/Classification Name: Computed Radiography, 21 CFR 892.1650

Proprietary Name: Computed Radiography (CR) Systems with NX 2.X Workstations

Agfa HealthCare Corporation
10 South Academy Street
Greenville, SC 29601

Contact: Jeffery A. Jedlicka, Prepared: April 18, 2007

Telephone: (864) 421-1815

Facsimile: (864) 421-1635

A. LEGALLY MARKETED PREDICATE DEVICES

This is a 510(k) for Agfa's computed Radiography Systems with NX 2.X Workstations.

The predicate devices are Agfa's Computed Radiography Systems with NX1.0 workstations (K053634).

B. DEVICE DESCRIPTION

The predicate and new devices are nearly identical computed radiography imaging systems. NX 2.X systems (new devices) have:

- An improved image processing package, Musica² Platinum (optional), provides improved image processing of the thorax, abdomen or musculoskeletal images for adult or pediatric patients.
- An auto-stitch function that allows users to automatically combine sub-images of large patient anatomies (a leg or spine, for example) into a single image.
- The ability to designate one workstation as the central workstation that has the ability to view exams on all connected workstations.

The basic principles of operation of the new and predicate devices are the same. They have the same underlying technological characteristics.

C. INTENDED USE

Agfa's Computed Radiography Systems with NX 2.X Workstations are intended for use in providing diagnostic quality images to aid the physician with diagnosis. The systems are suitable and capable of capturing and displaying two dimensional x-ray images of any anatomy.

Accessories are available that extend capability or user convenience when performing certain imaging procedures/anatomies including pediatric,

dental, full-length leg or spine, urology, tomography and radiotherapy planning and quality control.

Users of systems with NX 2.X software are able, with an optional Musica² Platinum software license, to generate improved quality images of the thorax, abdomen and musculoskeletal regions for adult and pediatric patients.

D. SUBSTANTIAL EQUIVALENCE SUMMARY

These Computed Radiography (CR) Systems with NX 2.X Workstations have the same indications for use as the legally marketed predicate devices (those with NX1.0 software), with the exception that the NX 2.X software will allow users to access enhanced image-processing software called Musica² Platinum. This capability will be available as an optional software license.

Musica² Platinum operates with similar algorithms to the predicate systems (K053634). The difference is that Musica² Platinum operates with algorithm parameters that are adjusted slightly to match images normally encountered in certain clinical applications. This image processing capability will be available as an optional software license. It will provide improved image processing for images of the thorax, abdomen and musculoskeletal regions for adult and pediatric patients.

E. TECHNOLOGICAL CHARACTERISTICS

The technological characteristics are the same in the proposed and predicate devices. Both the predicate and new devices use x-rays received by photostimulable plates to create latent diagnostic images. Plates are then scanned by a laser (or laser diode array) which converts the images into a digital form that can be previewed, adjusted if necessary, then stored locally, sent to an archive, printed or sent to a softcopy capable display such as a PACS system.

F. TESTING

Agfa's Computed Radiography (CR) Systems with NX 2.X Workstations have been tested for proper performance to specifications through various in-house and imaging performance tests. Components have been tested and shown to meet the requirements of EN 60601-1-1 and EN 60601-1-2.

Agfa Corporation

Premarket Notification: Computed Radiography Systems With NX 2.X Workstations

G. CONCLUSIONS

This 510(k) has demonstrated Substantial Equivalence as defined and understood in the Federal Food Drug and Cosmetic Act and various guidance documents issued by the Center for Devices and Radiological Health.



Food and Drug Administration
10903 New Hampshire Avenue
Document Control Room – WO66-G609
Silver Spring, MD 20993-0002

Agfa Healthcare Corporation
% Mr. Mark Job
Responsible Third Party Official
Regulatory Technology Services LLC
1394 25th Street NW
BUFFALO MN 55313

AUG 23 2013

Re: K071162
Trade/Device Name: Computed Radiography (CR) Systems with NX 2.X
Regulation Number: 21 CFR 892.1680
Regulation Name: Stationary x-ray system
Regulatory Class: II
Product Code: MQB
Dated: April 25, 2007
Received: April 26, 2007

Dear Mr. Job:

This letter corrects our substantially equivalent letter of May 8, 2007.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of

medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of *In Vitro* Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely Yours,



Janine M. Morris
Acting Director
Division of Radiological Devices
Office of In Vitro Diagnostic Device
Evaluation and Safety
Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known): K071162

Device Name: Computed Radiography (CR) Systems with NX 2.X

Indications for Use:

Agfa's Computed Radiography Systems with NX 2.X software are indicated for use in providing diagnostic quality images to aid the physician with diagnosis.

The systems can be used with either Musica, Musica² or Musica² Platinum image processing to create radiographic images of the skeleton (including skull, spinal column and extremities) chest, abdomen and other body parts.

When used with separately cleared accessories the systems can be conveniently used to generate urological, tomographic, pediatric and dental images, and for radiotherapy planning and quality control.

When used with Musica² Platinum software the systems are indicated for creating high quality images of the thorax, abdomen or musculoskeletal regions of adult or pediatric patients.

Agfa's Computed Radiography Systems with NX 2.X software are not indicated for use in mammography.

Prescription Use X AND/OR Over-The-Counter Use
(Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Janey C Brogdon
(Division Sign-Off)
Division of Reproductive, Abdominal, and
Radiological Devices
510(k) Number K071162